你买到的充电宝"中招"了吗？ 近期，由充电宝行业知名品牌安克、罗马仕所引发的质量风波，在消费者群体中引起了广泛关注。 3C认证证书被"暂停"、民航局禁止携带上机、罗马仕官宣停工停产6个月……随着关于充电宝安全问题的讨论在社交媒体上持续发酵，加之一系列不利消 息不断传来，无疑给消费者心中蒙上一层更深的阴影，让大家对充电宝的购买选择和日常使用变得越发谨慎。 一场由电芯材料变更所带来的产品信任危机，就此拉开充电宝行业洗牌的序幕。 超百万台充电宝被紧急召回 最近这几天，有关安克要召回充电宝产品的电话、短信齐上阵，这才让王琳知道，原来自己曾经购买过的A1642型充电宝，存在着巨大的安全隐患。 闻讯的王琳心里不禁咯噔一下，回想起自己使用这款充电宝的种种情景，即使彼时的它显得既笨重又极易发烫，但她也只是把这当成了正常现象，从日常 通勤到出差旅行，这款充电宝几乎成了她不可或缺的能量伙伴。 直到王琳按照官方提示，在召回连接中输入了自己的充电宝型号和购买信息，确认自己手里那款产品确实符合召回条件后，她的心情瞬间变得复杂起来。 产品召回流程 一方面，王琳非常庆幸，自己能够及时收到召回通知，避免了可能发生的安全事故；另一方面，王琳又 ...

中通客车第395、396批《道路机动车辆生产企业及产品公告》新产品公示 | 企业名称 | | 产品商标 | 产品名称 | 产品型号 | | --- | --- | --- | --- | --- | | 中通客车股份有限公司 | 中通牌 | | 纯电动低地板城市客车 | LCK6706EVGDA16 | | 中通客车股份有限公司 | 中通牌 | | 纯电动客车 | LCK6829EVA20 | | 中通客车股份有限公司 | 中通牌 | | 纯电动低地板城市客车 | LCK6856EVGDA17 | | 中通客车股份有限公司 | 中通牌 | | 纯电动客车 | LCK6119EV1A35 | | 中通客车股份有限公司 | 中通牌 | | 纯电动客车 | LCK6119EV1A15 | | 中通客车股份有限公司 | 中通牌 | | 纯电动客车 | LCK6125EV1A40 | | 中通客车股份有限公司 | 中通牌 | | 纯电动客车 | LCK6909EV1A25 | | 中通客车股份有限公司 | 中通牌 | | 纯电动客车 | LCK6125EV1A25 | | 中通客车股份有限公司 | 中通牌 | | 纯电 ...

如果您希望可以时常见面，欢迎标星收藏哦~ 来 源： 内容来自半导体芯闻综合 。 台积电分红开奖，受惠去年营收、获利攀新高，员工奖金及分红同步水涨船高。其中，2024年总 计将发出1,405.9亿元，年增幅逾4成，以员工人数7万人计算，平均每人可领超过200万元新台币 （约合人民币50万），并分成去年四包季分红及一大包年分红领取。 随后，陆续有员工分享开奖消息，其中33职等、年资6年的员工表示将拿「1.8M」史上最大包，还 开 心 道 「 M 是 百 万 谢 谢 」 ， 换 算 将 可 以 拿 到 180 万 ；32 职 等 、 年 资 5 年 、 考 绩 S+ 的 员 工 也 有 「1.16M」，约116万元。 台积电当时12日董事会核准2024年员工业绩奖金与酬劳（分红）总计约新台币1,405亿9,256万 元，其中员工业绩奖金约新台币702亿9,628万元已于每季季后发放，而酬劳（分红）约新台币702 亿9,628万元将于今年七月发放。 现在，这一切也几乎都符合预期。 而董事长魏哲家也改善员工分红领取制度，将不再与在职状态直接挂钩，现行制度会依在职纪录进 行发放，也造就创新低的离职率。 7月百万分红入帐， ...

Core Viewpoint - Intel's new CEO, Pat Gelsinger, is considering a significant shift in its wafer foundry strategy to attract major clients, potentially prioritizing the development of the next-generation 14A process over the previously planned Intel 18A process [1][2]. Group 1: Strategy and Development - Intel may halt marketing the 18A process to new clients as early as July, with a final decision possibly delayed until fall due to the complexity and financial implications involved [1]. - The company is currently in the risk production phase for the Intel 18A process, which is expected to reach mass production this year, but there are indications that resources may be redirected towards the 14A process [1][2]. - The 14A process is viewed as having the potential to surpass TSMC's technology in certain aspects, aiming to attract major clients like Apple and Nvidia, who currently rely on TSMC for their chip production [1]. Group 2: Financial Implications - If Intel decides to abandon the 18A and 18A-P processes, it may incur significant write-downs, potentially amounting to hundreds of millions or even billions of dollars [2]. - Intel's primary customers for the 18A process have been internal, with plans to produce the Panther Lake laptop chips, which are touted as the most advanced processors designed and manufactured in the U.S. [2]. Group 3: Client Commitments and Market Position - Intel has made commitments to Amazon and Microsoft to produce a limited quantity of chips using the 18A process, with set delivery timelines [2][3]. - TSMC has highlighted its advancements in 2nm and A16 process technologies, indicating a competitive edge in energy-efficient computing, with most innovators collaborating with TSMC [3].

Core Viewpoint - TSMC's recent technology forum in Shanghai highlighted the company's advancements in semiconductor technology and its market outlook, particularly focusing on the growth of the semiconductor market driven by high-performance computing (HPC) and AI integration, despite limitations in advanced process offerings to Chinese clients [3][4][5]. Market Outlook - The global semiconductor market is projected to exceed $1 trillion by 2030, with HPC accounting for 45%, smartphones for 25%, automotive for 15%, and IoT for 10% [5][6]. Advanced Process Technology - TSMC's 3nm family continues to evolve, with N3P expected to enter mass production in Q4 2024, enhancing performance by 5% or reducing power consumption by 5-10% compared to N3E [6][9]. - N2P is anticipated to begin production in H2 2026, offering an 18% performance increase at the same power level and a 36% reduction in power at the same performance level [11][13]. - The A16 process, set for mass production in H2 2026, integrates three innovative technologies, promising an 8-10% performance boost or a 15-20% reduction in power consumption compared to N2P [14][19][22]. - The A14 process, based on second-generation GAA technology, is expected to start production in 2028, with significant improvements in speed and energy efficiency [20][22]. Advanced Packaging Technology - TSMC's 3DFabric® technology includes SoIC platforms for 3D silicon stacking, with N3-on-N4 stacking expected to enter mass production in 2025 [23][25]. - The SoW-X platform, set for 2027, aims to enhance computational capabilities significantly, integrating essential components for AI training [30]. Special Process Technologies - TSMC is advancing automotive technology with its latest logic technologies, which enhance performance by approximately 20% per generation while reducing power consumption by 30-40% [32]. - The company is also focusing on IoT applications, with developments in ultra-low leakage SRAM and logic circuits to extend battery life [38]. Manufacturing Excellence - TSMC anticipates a twelvefold increase in wafer shipments for AI-related products by 2025 compared to 2021 [44]. - The company plans to add nine new facilities by 2025 to expand capacity, including six wafer fabs in Taiwan and two overseas [45]. - TSMC is committed to sustainable manufacturing, aiming for net-zero emissions by 2050 and a 98% resource recovery rate by 2030 [46][48].

Core Viewpoint - The company, Kelun-Botai, is a leading player in the ADC (Antibody-Drug Conjugate) sector, with a robust technology platform and significant backing from multinational corporations (MNCs) [1] Group 1: Company Overview - Kelun-Botai was established in 2016 as an innovative R&D subsidiary of Kelun Pharmaceutical, focusing on three major technology platforms: ADC, macromolecules, and small molecules [1] - As of the 2024 annual report, Kelun-Botai has over 30 innovative assets and more than 10 drugs in clinical stages, indicating a well-structured pipeline [1] - The company is expected to enter a rapid growth phase in 2025, with promising commercial progress anticipated [1] Group 2: ADC Platform Development - The ADC platform focuses on both oncology and non-oncology development strategies, with research capabilities endorsed by MNCs [1] - SKB264, an optimized drug based on trastuzumab, has a comprehensive layout for breast cancer and non-small cell lung cancer (NSCLC), with multiple approvals and submissions expected between 2024 and 2025 [2] - A166 has reached critical endpoints in phase II trials for advanced HER2+ breast cancer and is expected to receive approval in 2025 [2] - The early ADC pipeline includes various targets such as CLDN18.2 and Nectin-4, with new products like SKB571 and SKB107 anticipated to follow [2] Group 3: Non-ADC Platform Development - The non-ADC platform is entering a harvest phase, covering oncology and autoimmune fields [2] - A167 (PD-L1) has received approvals for multiple indications, while A140 (a biosimilar of cetuximab) is also set for approval in early 2025 [2] - A400, a selective RET inhibitor for RET+ NSCLC, is expected to submit for market approval within the year [2] Group 4: Financial Projections - Revenue forecasts for the company from 2025 to 2027 are projected at 2.006 billion, 2.884 billion, and 4.696 billion yuan, reflecting year-on-year growth rates of 3.8%, 43.8%, and 62.8% respectively [3] - The current stock price corresponds to price-to-sales (PS) ratios of 34.7x, 24.2x, and 14.8x for the respective years [3] - The company is expected to reach a commercialization inflection point in 2025, with numerous catalysts from clinical data and business development expectations [3]

Core Points - The Civil Aviation Administration of China (CAAC) has issued an emergency notice prohibiting passengers from carrying non-compliant power banks on domestic flights starting June 28, 2023 [1][2][3] - The notice emphasizes the need for enhanced security checks at airports to prevent passengers from bringing non-compliant power banks on board [2][3] Regulatory Changes - Power banks without a clear 3C mark, those that have been recalled, or those with unclear markings are banned from being carried onto flights [1][2] - Airports are required to set up designated areas for passengers to discard or temporarily store non-compliant power banks, ensuring clear procedures for these actions [2][3] Safety Concerns - There has been a rise in incidents involving power banks catching fire on flights, prompting the CAAC to implement stricter regulations based on international safety guidelines [3][5] - Recent recalls from major brands like Romoss and Anker due to safety risks associated with certain models have heightened the focus on power bank safety [4][5] Incident Reports - Multiple incidents of power banks igniting in-flight have been reported, including cases where flights had to return to the airport due to smoke from power banks [5][6] - The CAAC has strict requirements for power banks, including energy limits and usage restrictions during flights to mitigate fire risks [6]

南都此前报道，6月16日，深圳罗马仕科技有限公司宣布召回部分罗马仕牌PAC20-272、PAC20-392、 PLT20A-152型号移动电源，三款产品共计491745台。6月21日，安克创新（300866）科技股份有限公司 发布公告称，因部分批次基础款移动电源存在安全风险，即日起主动召回型号为 A1642/A1647/A1652/A1680/A1681/A1689/A1257的部分批次产品。 深圳宝安国际机场、长沙黄花国际机场客服人员均表示，"旅客不能携带罗马仕、安克两个品牌召回范 围内型号及批次的充电宝，召回型号及批次以外、符合规定的则不受影响。" 武汉天河国际机场工作人员告诉南都记者，"关于涉事两个品牌充电宝是否能携带，需要咨询搭乘航班 所在航司是否允许，安检一般只是劝解，建议旅客不要携带。且充电宝额定能量超过100Wh但不超过 160Wh的，也要航空公司批准。旅客可在航司值机柜台申请，拿着航司开具的放行单去过安检。" 此外，北京首都机场方面称，机场安检不看充电宝品牌，只要查验没有安全问题，满足标识清晰无破 损、额定能量在100Wh以内等要求是可以随身携带的。上海浦东机场安检热线工作人员表示，"已知悉 ...

Market Overview - US stock indices closed higher, with the Dow Jones up 0.75%, Nasdaq up 1.52%, and S&P 500 up 0.94% [1] - The VIX index fell 8.21% to 19.11, indicating reduced market volatility [1] - The US dollar index increased by 0.01% to 98.15, while the yield on the 10-year Treasury rose by 1.068% to 4.447% [1] - Spot gold decreased by 1.38% to $3385.2 per ounce, and Brent crude oil fell by 2.09% to $72.98 [1] Industry & Stocks - Most sectors in the S&P 500 saw gains, with semiconductors up 3.16%, communications up 1.72%, and technology up 1.62% [2] - Chinese concept stocks mostly rose, with TSMC up 2.17%, Alibaba up 2.74%, and Pinduoduo up 2.2% [2] - Major tech stocks also saw increases, including Microsoft up 0.88%, Nvidia up 1.92%, and Meta up 2.9% [2][15] - Circle, a crypto stablecoin company, saw its stock rise by 13.1% to $151, nearing five times its IPO price [3] - USA Rare Earth partnered with Moog to develop a supply chain for rare earth magnets for data centers, resulting in a 5.51% stock increase [4] - Uber's stock rose by 1.42% following a memorandum of understanding with Dubai's transport authority to initiate autonomous vehicle trials [5] - Boeing's stock increased by 0.69% despite lowering its 20-year aircraft demand forecast to approximately 43,600 units [6] Daily Focus - The USS Nimitz aircraft carrier is confirmed to be heading to the Middle East, marking a significant military deployment [7][8] - The US military has moved numerous refueling aircraft to Europe amid rising tensions in the Middle East, indicating strategic readiness [9][10] - OpenAI's partnership with Microsoft is reportedly under strain, with discussions about potential anti-competitive behavior and ownership stakes [13] - TSMC has completed its first batch of chip production in Arizona, producing over 20,000 wafers for major clients like Apple and Nvidia [14]

突破体外诊断领域"卡脖子"技术，东方生物液态芯片平台近期已在上海、西南地区多家全国知名三甲医 院等医疗机构投入使用，为肿瘤标志物、自身免疫等临床诊断提供可靠的技术支持。 液态芯片技术作为新一代生物检测平台，曾长期被国外巨头垄断，是我国体外诊断领域的技术瓶颈。东 方生物成功构建了具有完全自主知识产权的液态芯片技术体系，填补了国内空白，为临床诊断带来高通 量、高灵敏度的国产化解决方案。 与国际先行者Luminex相比，东方生物凭借完全自主可控的国产化平台，实现了"更高性能、更低成 本"的突破。 目前，东方生物正将液态芯片平台由人体诊断向动物检测与食品安全领域拓展。 全场景方案赋能精准诊断 目前，东方生物液态生物芯片平台(含微球、试剂、配套仪器)已进入产业化和市场化阶段，公司正加速 将技术优势转化为临床价值。 在核心设备方面，东方生物于2023年推出业内首款双功能免疫分析仪Mplex-MA1600，创新性地整合流 式荧光与化学发光技术，实现了多联检与单项快检的高效融合。2024年，针对分子多联检及小样本量需 求，公司又推出单机版流式点阵仪Mplex-M100。面对国产设备普遍存在的效率与稳定性短板，新一代 流式荧光 ...